FAK-IN-31
FAK-IN-31 is a FAK inhibitor with antiproliferative activity against a variety of cancer cell lines. FAK-IN-31 serves as a PROTAC target protein ligand for the development of FAK-targeted PROTAC degrader heads, such as PROTAC FAK degrader 5 (HY-183768). FAK-IN-31 can be used in the research of colorectal cancer, pancreatic cancer, breast cancer, hepatocellular carcinoma and lung cancer.
For research use only. We do not sell to patients.
- Formula: C22H17F3N4O3
- Molecular Weight:442.39
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
FAK-IN-31 (compound 5c) (72 h) potently inhibits the proliferation of multiple human cancer cell lines, including colorectal cancer HCT-15 and HCT116 cells with IC50 values of 0.65 μM and 1.12 μM, respectively, and exhibits relatively low cytotoxicity toward normal human L02 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
Molecular Weight 442.39
-
Formula C22H17F3N4O3
-
SMILES
O=C(NCC#C)C1=CC=C(NC2=NC=C(C(F)(F)F)C(OC3=CC=CC=C3OC)=N2)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)